Tyk2-IN-4 (BMS-986165) (Synonyms: BMS-986165) |
Katalog-Nr.GC31659 |
Tyk2-IN-4 (BMS-986165) (BMS-986165) ist ein hochselektiver, oral bioverfÜgbarer allosterischer TYK2-Inhibitor zur Behandlung von Autoimmunerkrankungen, der selektiv an die TYK2-Pseudokinase (JH2)-DomÄne (IC50=1,0 nM) bindet und blockiert rezeptorvermittelte Tyk2-Aktivierung durch Stabilisierung der regulatorischen JH2-DomÄne.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1609392-27-9
Sample solution is provided at 25 µL, 10mM.
Tyk2-IN-4 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).
Tyk2-IN-4 blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein[1].
Lupus-like disease is strongly inhibited in NZB/W mice treated with Tyk2-IN-4. Tyk2-IN-4 is safe and overall well-tolerated. There are no serious adverse events and the frequency of non-serious adverse events are similar in the active (75%) and placebo (76%) groups. After oral administration, Tyk2-IN-4 is rapidly absorbed and exhibits an apparent elimination half-life of 8-15 hours[1].
[1]. I Catlett, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2.
Average Rating: 5
(Based on Reviews and 35 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *